Records containing: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-04-16
  A Three-Part, Phase 1/2a, Randomized, Double-blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With MASLD
• CLINICAL_TRIALS study record update · 2026-04-14
  A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• CLINICAL_TRIALS study record update · 2026-03-31
  A Single-center, Phase II Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Effect of S-adenosyl-L-methionine (SAMe) in Prevention of Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD)-Related Cirrhosis
• CLINICAL_TRIALS study record update · 2026-03-18
  The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
• CLINICAL_TRIALS study record update · 2026-02-25
  Risk Factors and Prognosis of Metabolic Dysfunction-Associated Steatotic Liver Disease
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2026-02-11
  A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• CLINICAL_TRIALS study record update · 2025-07-25
  Prediction of Recompensation and Stable Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness Combined With Non-Invasive Markers: A Prospective, Observational, Multicenter Study